首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1452444

蛋白質工程市場-按產品（儀器、試劑、軟體和服務）、技術（非理性、理性）、蛋白質（胰島素、單株抗體、疫苗、生長因子、凝血因子、干擾素）、最終用途-全球預測， 2024年- 2032

Protein Engineering Market - By Product (Instrument, Reagent, Software & Services), Technology (Irrational, Rational), Protein (Insulin, Monoclonal Antibody, Vaccine, Growth Factor, Coagulation Factor, Interferon), End-use-Global Forecast, 2024-2032

出版日期: 2024年02月01日 | 出版商:

Global Market Insights Inc. | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在新創公司大量投資的推動下，全球蛋白質工程市場規模預計 2024 年至 2032 年間CAGR將超過 15.9%。創新企業的湧入為該行業注入了活力，推動了基於蛋白質的療法、工業酶和生物催化劑的進步。例如，2023 年11 月，荷蘭-瑞士新創公司Cradle 在第一輪融資中獲得了2,400 萬美元，以推進其生成人工智慧(GenAI) 和合成生物學平台，用於製作基於蛋白質的療法和其他化合物。

新創公司日益成長的興趣也反映出人們認知到蛋白質工程在應對醫療保健和工業挑戰方面的關鍵作用。這些投資的升級可能為變革性研究培育肥沃的土壤，有望重塑醫學、生物技術等領域的模式。

整個市場分為產品、技術、蛋白質類型、最終用途和地區。

就產品而言，從2024年到2032年，儀器領域的蛋白質工程產業複合CAGR預計將達到15.9%。對於從事新型蛋白質療法和工業酵素開發的研究人員和科學家來說，尖端工具已變得不可或缺。隨著技術的快速進步，對高通量篩選系統、蛋白質純化設備和分析儀器以簡化蛋白質工程流程的需求不斷成長。製造商日益關注創新以滿足不斷變化的需求，這將進一步推動該細分市場的成長。

基於技術，來自非合理蛋白質設計領域的蛋白質工程市場收入從 2024 年到 2032 年將實現 15.8% 的CAGR。這種創新方法涉及偏離傳統的蛋白質結構原理，創造新的功能和特性。研究人員擴大探索不合理的蛋白質設計，為治療和工業過程中的各種應用開發客製化的解決方案。人們對專業工具、計算模型和專業知識的興趣日益濃厚，將促進該細分市場的擴張。

歐洲蛋白質工程市場從 2024 年到 2032 年將呈現 16% 的CAGR。由於高度重視生物技術和醫療保健創新，一些歐洲國家正在推動基於蛋白質的療法、工業酶和生物催化劑的進步。研究機構和生物技術公司的強大生態系統以及政府舉措的湧入正在支持整個地區的蛋白質工程研究和開發。對尖端技術和合作項目的投資激增也將有助於區域產業的成長。例如，2024 年 3 月，德國著名生物公司 BRAIN Biotech AG 和先進材料領域的全球領導者 AMSilk GmbH 宣布成功完成合作開發工作的初始階段。經過一年的共同努力，他們已經實現了天然結構蛋白的顯著最佳化。

產業生態系統分析
產業影響力
- 成長動力
  - 蛋白質缺乏疾病的盛行率上升
  - 蛋白質藥物的採用率高於非蛋白質藥物
  - 增加生物製藥產業的研發活動
  - 蛋白質工程的融資機會不斷增加
- 產業陷阱與挑戰
  - 蛋白質工程技術成本高
  - 合格研究人員的數量有限
成長潛力分析
技術景觀
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

主要趨勢
儀器
試劑
軟體與服務

第 6 章：市場估計與預測：按技術分類，2018 年 - 2032 年

主要趨勢
不合理的蛋白質設計
合理的蛋白質設計

第 7 章：市場估計與預測：按蛋白質類型，2018 - 2032

主要趨勢
胰島素
單株抗體
疫苗
生長因子
凝血因子
干擾素
其他蛋白質類型

第 8 章：市場估計與預測：按最終用途，2018 - 2032 年

主要趨勢
學術研究機構
合約研究組織 (CRO)
製藥和生物技術公司

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Agilent Technologies, Inc.
Amgen Inc.
Bio-Rad Laboratories, Inc.
Bristol Myers Squibb Company
Bruker Corporation
Danaher Corporation
Genentech, Inc.
Integrated DNA Technologies, Inc.
Lonza Group
Merck KGaA
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Incorporated

簡介目錄

Product Code: 8008

Global Protein Engineering Market size is projected to accrue over 15.9% CAGR between 2024 and 2032, propelled by substantial investments from startups. The influx of innovative ventures is injecting dynamism into the industry, driving advancements in protein-based therapeutics, industrial enzymes, and biocatalysts. For instance, in November 2023, Dutch-Swiss startup Cradle secured 24 million in its first-round financing to advance its generative AI (GenAI) and synthetic biology platform for crafting protein-based therapeutics and other compounds.

The burgeoning interest from startups also reflects the recognition of the pivotal role of protein engineering in addressing healthcare and industrial challenges. The escalation of these investments is likely to foster a fertile ground for transformative research, promising to reshape the landscape of medicine, biotechnology, and beyond.

The overall market is classified into product, technology, protein type, end-use and region.

In terms of product, the protein engineering industry from the instruments segment is set to record 15.9% CAGR from 2024 to 2032. Cutting-edge tools have grown indispensable for researchers and scientists engaged in the development of novel protein-based therapeutics and industrial enzymes. With the rapid technology advancements, there is a growing need for high-throughput screening systems, protein purification equipment, and analytical instruments to streamline the protein engineering process. The surging focus of manufacturers on innovations to meet the evolving needs will further drive the segment growth.

Based on technology, the protein engineering market revenue from the irrational protein design segment will register a 15.8% CAGR from 2024 to 2032. This innovative approach involves deviating from conventional protein structure principles to create novel functionalities and properties. Researchers are increasingly exploring irrational protein designs to develop tailor-made solutions for diverse applications in therapeutics, and industrial processes. The rising interest in specialized tools, computational models, and expertise will add to the segment expansion.

Europe protein engineering market will showcase 16% CAGR from 2024 to 2032. With a strong focus on biotechnology and healthcare innovation, several European countries are driving advancements in protein-based therapeutics, industrial enzymes, and biocatalysts. The robust ecosystem of research institutions and biotech companies along with the influx of government initiatives are supporting protein engineering research and development across the region. The surging investments in cutting-edge technologies and collaborative projects will also contribute to the regional industry growth. For instance, in March 2024, BRAIN Biotech AG, a prominent German biologizing company, and AMSilk GmbH, a global leader in advanced materials, announced the successful conclusion of the initial phase of their collaborative development effort. Following a year of joint endeavors, they have achieved significant optimization of a natural structural protein.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of protein-deficient diseases
  - 3.2.1.2 Increase in adoption of protein drugs over non-protein drugs
  - 3.2.1.3 Increasing research & development activities in the biopharmaceutical industry
  - 3.2.1.4 Growing funding opportunities for protein engineering
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High costs of protein engineering techniques
  - 3.2.2.2 Limited availability of qualified researchers
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutess
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Reagents
5.4 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Irrational protein design
6.3 Rational protein design

Chapter 7 Market Estimates and Forecast, By Protein Type, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Insulin
7.3 Monoclonal antibodies
7.4 Vaccines
7.5 Growth factors
7.6 Coagulation factors
7.7 Interferon
7.8 Other protein types

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Academic research institutes
8.3 Contract research organizations (CROs)
8.4 Pharmaceutical & biotechnology companies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa